Parkinson disease and Multiple Sclerosis patients in their randomized
Participating registered nurses and our supplier, NuPlasma, all worked diligently to meet our prescriptive requirements, administering extraordinarily high-quality yFFP, which NuPlasma segmented not only by age but also by gendere are cautiously optimistic that the patients that received the NuPlasma infusions will continue to improve in the coming months, a progression which we will strictly scrutinize and document. Only one month into the double-blind, placebcontrolled study, designed to evaluate the efficacy of 25 ml/kg intravenously delivered oung plasma (volunteer donated blood plasma from adults between the ages of 18-25 years old), administered in two doses over three days, positive changes in blood biomarkers and life quality among MS patients, and a motor-examed PD patient, have been documented.D. Ginsberg, also speaking on behalf of study participantsIgor Cherches, M., said,8220;We are pleased to be involved in a sound, scientifically structured study that evaluates the ability of immediately obtainable young Fresh Frozen Plasma (yFFP) to slow, or prevent the progression of Parkinson8217;s disease, Multiple Sclerosis and ultimately with further research, other age-related China single phase motor Manufacturers degenerative diseases.
One-month results for all forty patients are expected to be released in early February 2019, three-month results in April and the six-month, final study assessments are to be concluded by July. The trending of observed biomarkers points toward a gradual improvement in the debilitating condition after only the first month of yFFP infusions, verifiable by the placebo test.The Neurology Center, a medical group practice of top doctors devoted to excellence in care, located inHouston, Texas, working in conjunction with two leading neurology and anti-aging Houston based specialists announced completing infusions for thirty-four of the forty Parkinson disease and Multiple Sclerosis patients in their randomized, controlled study of intravenously administered young Fresh Frozen Plasma (yFFP) provided byNuPlasma and the initial test results of four of the MS patients.(ABAARM, FAARFM), the 2018 A4M Congress Advances and Applications in Regenerative Medicine session moderator and oung Plasma Transfusions for MS, Parkinson and Overall Longevity presenter. It is our objective to determine from this study if subjective insights from the previous infusions of non-study patients and encouraging advances identified today from those patients receiving yFFP vs the saline placebo, confirm the practical use of yFFP to treat Parkinson8217;s disease and Multiple Sclerosis,8221;saidDian Ginsberg, M./em>Continuing results from this study will be made available to the public on the website: http://YoungPlasmaStudy.D./em>Dr.8220;The completion of infusions into all forty patients will mark a significant milestone.com/.D. fromThe Neurology Centerand neurologistEddie Patton, M
برچسب: ،